Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.
This study is a very early stage trial, called a Phase 1 study. Its main goal is to test a new medicine, IM-250, in healthy volunteers for the first time. We want to understand if it's safe to use, how well people tolerate it (meaning, how they feel when they take it), and how the body handles the medicine after it's given through a drip (an IV). We'll be giving different doses to see how these things change. This research is crucial because the information gathered will help doctors decide if IM-250 is promising enough to be studied further as a potential treatment for conditions like herpes simplex virus encephalitis, a serious infection that causes brain swelling.
At a glance
What is this study about?
This study is all about understanding a new medicine called IM-250. Because it's a new medicine, we first need to make sure it's safe to give to people. This type of study, called a Phase 1 trial, is one of the very first steps in developing new treatments. We'll be giving IM-250 through a drip directly into a vein (known as an IV) to healthy people, meaning they don't currently have any serious health problems. We'll gradually increase the amount of medicine given to different groups of volunteers.
The main things we want to find out are: is IM-250 safe? Can people take it without too many uncomfortable side effects? And how does the body process the medicine? This includes how quickly it gets into the blood, how long it stays there, and how the body gets rid of it. Understanding these things is really important before we can even think about giving IM-250 to people who are unwell.
The information we collect from healthy volunteers in this study is vital. It helps scientists and doctors decide if IM-250 has the potential to become a treatment for serious conditions in the future, like herpes simplex virus encephalitis. This is a very serious infection that affects the brain and can have life-threatening consequences. Starting with healthy volunteers allows us to learn about the drug in a controlled way before moving on to sicker patients, always prioritising safety.
Key takeaways
- This is a safety study for a new medicine called IM-250.
- It's the first time IM-250 is being given to healthy people.
- The main goals are to check if it's safe, how well it's tolerated, and how the body processes it.
- The information gained could help develop future treatments for serious brain infections.
- Participants must be healthy adults aged 18 or older.
- Taking part helps advance medical science, but there are potential risks involved.
Who may be eligible?
To join this study, you need to be an adult, 18 years or older. The study is open to both men and women.
Because this is a very early safety study, we are looking for generally healthy people. This means you shouldn't have any major ongoing medical conditions that could make taking a new medicine risky. The medical team will check your health carefully to make sure it's safe for you to take part.
There might be other specific health requirements or conditions that would prevent you from joining, but these would be discussed in detail by the study doctor if you express interest.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy, without major ongoing medical conditions?
- Are you able to attend all required study visits?
- Are you comfortable receiving medicines through an IV drip?
- Are you willing to follow all study instructions?
What does participation involve?
If you decide to take part, you'll first have a screening visit to check your health and make sure you're suitable for the study. If you qualify, you'll receive the study medicine, IM-250, through a drip into your arm. This will happen over a set period, and you'll be carefully watched by the medical team during and after the infusion. They will take blood samples and check your vital signs (like heart rate and blood pressure) regularly.
There will also be follow-up visits or phone calls to monitor your health and any side effects. The total duration of your participation, including all visits and follow-ups, will be clearly explained to you before you agree to join. You will be told exactly how many visits are needed and how long each visit might take.
Potential risks and benefits
Locations (1)
- —UnverifiedBulgaria
Common questions
What is a 'Phase 1' study?
A Phase 1 study is a very early stage of research where a new medicine is tested in people for the first time, usually in healthy volunteers. The main goal is to check for safety and how the body handles the medicine.
What does 'herpes simplex virus encephalitis' mean?
It's a serious infection that can cause swelling and damage to the brain. This study is not treating this condition, but the medicine being tested could potentially help people with it in the future.
Will I get paid for taking part?
Reimbursement for your time, travel, and inconvenience is often provided in studies like this. The study team will give you all the details if you are eligible and interested.
What happens if I feel unwell during the study?
The medical team will be closely monitoring you throughout your participation. If you feel unwell, you should tell them immediately, and they will provide care and support.
How long does the study last for each person?
The exact duration for each person will be explained by the study team during the initial screening process. It will include the time spent receiving the medicine and for follow-up checks.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.